About CLINUVEL

Announcements

CLINUVEL's company releases, including archives.

Tuesday, 07 November 2017 19:24

Response to ASX Price Query

Monday, 30 October 2017 19:20

Appendix 4C

Melbourne, Australia, and Leatherhead, UK, 30 October 2017 CLINUVEL PHARMACEUTICALS LTD (ASX: CUV; XETRA-DAX: UR9; NASDAQ INTERNATIONAL DESIGNATION ADR: CLVLY), a global biopharmaceutical company focused on developing and delivering treatments for patients with a range of severe and therapeutically unmet genetic disorders today announced its Appendix 4C – Quarterly Cashflow report for the period ended 30 September 2017.The cash balance as at 30 September 2017 was $26,180,000, an increase of $2,428,000 from the 30 June 2017 cash balance. This follows a $4,981,000 increase in the overall cash balance reported in the previous Appendix 4C report.Cash receipts for the quarter were…
Friday, 27 October 2017 08:48

Appendix 4G

Tuesday, 17 October 2017 09:42

CLINUVEL Newsletter - October 2017

Tuesday, 10 October 2017 17:42

CLINUVEL CONFIRMS AGM DATE

CLINUVEL CONFIRMS AGM DATE Leatherhead, UK and Melbourne, Australia, 10 October 2017 CLINUVEL PHARMACEUTICALS LTD [ASX: CUV; NASDAQ INTERNATIONAL DESIGNATION: CLVLY; XETRA-DAX: UR9] today announced it will hold its 2017 Annual General Meeting of shareholders on Tuesday 28 November 2017 at 10.00am AEDT at Arnold Bloch Leibler, Level 21, 333 Collins Street, Melbourne, Victoria, Australia 3000. A formal Notice of Meeting and the Company’s Annual Report will be lodged with the ASX no later than 27 October 2017.- End - About CLINUVEL PHARMACEUTICALS LIMITED CLINUVEL PHARMACEUTICALS LTD (ASX: CUV; NASDAQ INTERNATIONAL DESIGNATION ADR: CLVLY; XETRA-DAX: UR9) is a global biopharmaceutical…
Wednesday, 04 October 2017 17:59

ELIE ISHAG TO RETIRE FROM CLINUVEL BOARD

ELIE ISHAG TO RETIRE FROM CLINUVEL BOARDMelbourne, Australia and Leatherhead, UK, 04 October 2017 CLINUVEL PHARMACEUTICALS LTD [ASX: CUV; NASDAQ INTERNATIONAL DESIGNATION: CLVLY; XETRA-DAX: UR9] today announced that Mr Elie Ishag has advised that he will not stand for re-election as Non-Executive Director of CLINUVEL at the Company’s 2017 Annual General Meeting. He will continue to serve on the Board of CLINUVEL until the date of the Meeting. Mr Ishag has been a shareholder of the Company for 12 years and has served on the Board of Directors since February 2011. He has been a member of the Remuneration Committee…
CLINUVEL TO SUBMIT EUROPEAN POST-MARKETING DATA AS PART OF NDA FOR EPPMelbourne, Australia and Leatherhead, UK, 19 September 2017 EUROPEAN POST-MARKETING SAFETY DATA TO BE SUBMITTED AS PART OF NEW DRUG APPLICATION (NDA), EXPECTED IN DECEMBER 2017 NO RISK EVALUATION & MITIGATION STRATEGIES (REMS) EXPECTED BUT A SIMILAR POST-MARKETING PROGRAM AS IN EUROPE FDA ANSWER IS EXPECTED TO THE REQUEST FOR PRIORITY REVIEW FAST TRACK = ROLLING REVIEW CLINUVEL PHARMACEUTICALS LTD [ASX: CUV; NASDAQ INTERNATIONAL DESIGNATION: CLVLY; XETRA-DAX: UR9] today announced an update on its submission of the New Drug Application (NDA) for CLINUVEL’s drug SCENESSE® (afamelanotide 16 mg) to…
Wednesday, 06 September 2017 17:37

Appendix 3B

Page 1 of 48

Latest Company Announcements

07 November 2017

Response to ASX Price Query

Response to ASX Price Query

Read More
30 October 2017

Appendix 4C

Appendix 4C

Read More
26 October 2017

Appendix 4G

Appendix 4G

Read More
16 October 2017

CLINUVEL Newsletter - October 2017

I am addressing you during quite a turbulent period, when our teams are preparing various dossiers to meet regulatory obligations in Europe and the US

Read More
10 October 2017

CLINUVEL CONFIRMS AGM DATE

CLINUVEL PHARMACEUTICALS LTD today announced it will hold its 2017 Annual General Meeting of shareholders on Tuesday 28 November 2017

Read More

Quick Links